Develops drugs for pulmonary hypertension.
Dec 2025Revenue $0.00/yrExpenses $56.4M/yr
Fell below break-even Nov 2011Cash runway ≈ 2.6 years from Jun 2026
Figures by year
When will Tenax Therapeutics be profitable again?
Its expenses passed its revenue in Nov 2011. In the 12 months to Dec 2025, revenue was $0.00 and expenses $56.4M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $0.00 | $56.4M | −$56.4M |
| Dec 2024 | $0.00 | $19.5M | −$19.5M |
| Dec 2016 | $0.00 | $52.7M | −$52.7M |
| Apr 2015 | $49.3K | $14.9M | −$14.8M |
| Apr 2014 | $159K | $16.8M | −$16.6M |
| Apr 2013 | $1.19M | $6.38M | −$5.19M |
| Apr 2012 | $364K | $8.58M | −$8.22M |
| Apr 2011 | $103K | −$10.5M | $10.6M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.